Want to cut your energy bills? Here’s how five experts are doing it 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2017 -- Fluidigm Corporation (NASDAQ:FLDM) today announced that Chris Linthwaite, President and CEO, will present at the Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 9:20 am ET in Boston, Massachusetts. The live audio webcast of the company’s presentation and subsequent replay may be accessed at http://wsw.com/webcast/cowen38/fldm. The webcast will be archived for 90 days following the live presentation.
About Fluidigm
Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for markets such as mass cytometry, high-throughput genomics, and single-cell genomics. We sell to leading academic institutions, clinical research laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multiparameter mass cytometry technology and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
We use our website (www.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (https://www.facebook.com/fluidigm), and LinkedIn page (https://www.linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.
Fluidigm and the Fluidigm logo are registered trademarks of Fluidigm Corporation.
Contact: Fluidigm Corporation Ana Petrovic Director, Corporate Development and Investor Relations 650 243 6628 (office) [email protected]
